Clinical trial NCT03133923: Phase II of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants
Official title: Safety and Efficacy of Attenuated Mumps Vaccine (Human Diploid Cell)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Epidemic Parotitis,Mumps
Keywords: Attenuated Mumps Vaccine(F-genotype，Human Diploid Cell, KMB-17), safety, immunogenecity
Lead sponsor: Institute of Medical Biology, Chinese Academy of Medical Sciences
Sponsor class: OTHER
Collaborators: name: Hubei Provincial Center for Disease Control and Prevention
First posted: 2017-04-28
Enrollment: 1080
Sex: ALL
Minimum age (years): 8
Maximum age (years): 24
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Mumps is an acute infectious respiratory disease caused by the mumps virus (MuV), which occurs mainly in children and adolescents. Its main clinical symptoms were parotid gland suppurative swelling and pain with fever. The pathological changes and harm caused by mumps was not only confined to the parotid gland, on the contrary, the social harm caused by serious complications cannot be ignored. As mumps is a vaccine-preventable infectious disease, vaccination is a fundamental strategy for controlling mumps. So far, there are 13 genotypes of MuV. Based on the analysis of molecular epidemiology, the main epidemic strain of MuV in China was the F genotype. The commonly used vaccine strains represented only a small number of known genotypes, e.g. Jeryl-Lynn (JL) and Rubini strains, which belong to type A, Urabe strain belongs to type B, and L-Zagreb strains belongs to type D. Virus seed of Live Attenuated Mumps Vaccine (Human diploid cell) developed by the institute was SP-A strain, which was the first separation and preparation of the attenuated mumps viruses in China. SP-A belongs to F genotype, which was the domestic epidemic genotype. In addition, the cell substrate prepared for vaccine was human diploid cell (KMB-17 strain), which is much safer to use. The preliminary test results showed that the vaccine possessed good immunogenicity and good antigenic cross-reactivity. The application of this vaccine will provide more effective means to prevent and control of mumps epidemic.

Detailed description: In order to evaluation the safety and immunogenicity of different doses Live Attenuated Mumps Vaccine (Human diploid cell).The study will Determine the optimal dose of vaccine and provide the clinical trail basis for the phase Ⅲ trail design.

Primary objective:

After single dose immunization of low dose(≥3.0but\<3.5lgCCID50)、high dose （≥4.5lgCCID50）Live Attenuated Mumps Vaccine (Human Diploid Cell) in Chinese healthy Infants volunteer aged from 8 to 24 months old.the study will evaluate the standardized positive rate of neutralizing antibody and the GMT of the hemagglutination inhibition antibody and neutralizing antibody,proposing the immune reference dose for phase III clinical trials.

Secondary objective： Evaluate the safety of low dose(≥3.0but\<3.5lgCCID50)、high dose （≥4.5lgCCID50）Live Attenuated Mumps Vaccine (Human Diploid Cell) in Chinese healthy Infants volunteer aged from 8 to 24 months old.

Eligibility criteria: Inclusion Criteria:

* Healthy males and females (from 8 months to 24 months old) as determined by medical history, physical examination, laboratory examination and clinical judgment of the investigator.
* Provided legal identification for the sake of recruitment.
* Without the routine corticosteroids of vaccination .
* Never has gone down with mumps or taken a vaccine contain mumps.
* parent(s)/legal guardian(s) are able to understand and sign informed consents and be able to read a thermometer and dividing ruler .At the same time,the parent(s)/legal guardian(s)should have the ability and objective to comply with the requirements of the protocol.
* Participants or guardians are able to attend all planned clinical appointment and obey and follow all study instructions; can persist for a 1-month visit and receive blood sample and throat swab collection according to program requirements.
* Axillary temperature ≤37℃.

Exclusion Criteria:

* Subject who has a medical history of Mumps or taken a vaccine contain mumps.
* Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine
* Convulsant,encephalopathy,psychosis or family histoty of epileptics.
* Clinical diagnosis of coagulopathy (such as clotting factor deficiency, coagulation disorders, platelet abnormalities), significant bruising or blood clotting disorder,it will couse the contraindication of subcutaneous injection
* Any prior administration of attenuated live vaccine in last 15 days;Any prior administration of subunit or inactivated vaccines in last 7 days
* Any prior administration of other research medicines in last 30 days.
* Any prior administration of blood products(immunoglobulin etc.) in last 1 month;Any prior administration of immunodepressant ，cytotoxic drugs or corticosteroids in last 6 months(except the corticosteroids spray can treat irritability rhinitis orcorticosteroids to cure noncomplication acute dermatitis ).
* Any confirmed or suspected autoimmune disease or immune deficiency diseases(like favism or other diseases etc. ), including human immunodeficiency virus (HIV) infection.
* Suffering from congenital deformity or serious chronic disease(congenital heart disease，Down's syndrome,diabetes,sickle cell anemia,nervous illness,cardiocardiopathy,hypertension,bronchitis,pneumonia,asthma,infectious skin diseases)
* Acute or chronic infectious disease,active infectious;Laboratory test show Routine blood abnormal or hepatorenal dysfunction.
* Malignant disease(like cancer)，heredopathia or other disease that will cuase eccyliosis.The spleen or other important organ has been removed for any reason.
* Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives.

Primary outcomes:
measure: Positive conversion rate of Muv hemagglutination inhibition antibody of different single dose of Muv Vaccine
timeFrame: the 0 days（before vaccination） and 28 day after the vaccination
measure: Positive conversion rate of Muv neutralization antibody of different single dose of Muv Vaccine
timeFrame: the 0 days（before vaccination） and 28 day after the vaccination
Secondary outcomes:
measure: The GMT of the hemagglutination inhibition antibody and neutralizing antibody
timeFrame: the 0 days（before vaccination） and the 28 day after the vaccination
measure: The GMT of the neutralizing antibody
timeFrame: the 0 days（before vaccination） and the 28 day after the vaccination
measure: The incidence rate of ADR after vaccination
timeFrame: within the first 28 days after the vaccination
measure: viral shedding after the vaccination
timeFrame: the 0（before vaccination）,4,10 days after the vaccination
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Hubei Provincial Center for Disease Control and Prevention
state: Hubei
Study officials:
affiliation: Hubei Provincial Center for Disease Control and Prevention
name: Beifang Yang, PhD
role: PRINCIPAL_INVESTIGATOR
References: